scholarly journals Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients

2020 ◽  
Vol 21 (10) ◽  
pp. 3532 ◽  
Author(s):  
Francesca Pirini ◽  
Luigi Pasini ◽  
Gianluca Tedaldi ◽  
Emanuela Scarpi ◽  
Giorgia Marisi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Progression Free Survival ◽  
Vascular Endothelial ◽  
Free Survival ◽  
Antiangiogenic Treatment ◽  
Tetranucleotide Repeats ◽  
Few Data ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

Very few data are reported in the literature on the association between elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) and prognosis in advanced colorectal cancer. Moreover, there is no information available in relation to the response to antiangiogenic treatment. We analyzed EMAST and vascular endothelial growth factor-B (VEGF-B) microsatellite status, together with standard microsatellite instability (MSI), in relation to prognosis in 141 patients with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT) alone (n = 51) or chemotherapy with bevacizumab (B) (CT + B; n = 90). High MSI (MSI-H) was detected in 3% of patients and was associated with progression-free survival (PFS; p = 0.005) and overall survival (OS; p < 0.0001). A total of 8% of cases showed EMAST instability, which was associated with worse PFS (p = 0.0006) and OS (p < 0.0001) in patients treated with CT + B. A total of 24.2% of patients showed VEGF-B instability associated with poorer outcome in (p = 0.005) in the CT arm. In conclusion, our analysis indicated that EMAST instability is associated with worse prognosis, particularly evident in patients receiving CT + B.

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

2016 ◽  
Vol 55 (11) ◽  
pp. 1381-1394 ◽  
Author(s):  
Morgane Caulet ◽  
Thierry Lecomte ◽  
Olivier Bouché ◽  
Jérôme Rollin ◽  
Valérie Gouilleux-Gruart ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Free Survival ◽  
Colorectal Cancer Patients

scholarly journals Metastatic colorectal cancer patients who achieved long progression-free survival by regorafenib or TAS-102 therapy

2016 ◽  
Vol 27 ◽  
pp. vii78
Author(s):  
Yosuke Kito ◽  
Satoshi Hamauchi ◽  
Kentaro Yamazaki ◽  
Azusa Komori ◽  
Toshiki Masuishi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Free Survival ◽  
Colorectal Cancer Patients

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

2011 ◽  
Vol 17 (19) ◽  
pp. 6329-6337 ◽  
Author(s):  
Nicolas Azzopardi ◽  
Thierry Lecomte ◽  
David Ternant ◽  
Michelle Boisdron-Celle ◽  
Friedrich Piller ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Free Survival ◽  
Colorectal Cancer Patients

scholarly journals A comparison of FOLFIRI (Folinic Acid, Fluorouracil and Irinotecan) Plus Bevacizumab and FLOLFIRI Plus Aflibercept as Second-Line Treatment for Metastatic Colorectal Cancer

2020 ◽  
Author(s):  
Min-Sang Lee ◽  
Yong-Pyo Lee ◽  
Hongsik Kim ◽  
Jung Yong Hong ◽  
Jeeyun Lee ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Folinic Acid ◽  
Progression Free Survival ◽  
Line Treatment ◽  
Second Line ◽  
Free Survival ◽  
Treatment Groups ◽  
Grade 3 ◽  
Colorectal Cancer Patients

Abstract Background: To date, there are few clinical studies comparing the efficacy and safety of FOLFIRI (folinic acid, fluorouracil and irinotecan) plus bevacizumab or aflibercept in metastatic colorectal cancer patients (mCRC) pretreated with oxaliplatin-based chemotherapy. Methods: We analyzed the treatment outcomes of patients receiving FOLFIRI in combination with bevacizumab or aflibercept as second-line treatment for mCRC between October 2017 and March 2020. This analysis included 67 patients receiving FOLFIRI plus aflibercept and 83 receiving FOLFIRI plus bevacizumab. Results: The overall response rate (ORR) was 13.6% (95% CI: 4.85-22.34) in the FOLFIRI-aflibercept group and 14.7% (95% CI: 6.68-22.71) in the FOLFIRI-bevacizumab group. This difference in ORR was not statistically significant. The median progression free survival (PFS) was 8.6 months in the FOLFIRI-bevacizumab group and 8.5 months in the FOLFIRI-aflibercept group (P = 0.752) (Fig. 1). Patients in the FOLFIRI-bevacizumab group showed a median overall survival (OS) of 12.4 months, while patients in the FOLFIRI-aflibercept group had a median OS of 13.7 months (P = 0.276). There were no significant differences in survival between the two treatment groups. The adverse events were also largely similar between the two groups. However, hypertension of grade 3 or more was more frequent in the FOLFIRI-aflibercept group. Conclusion: FOLFIRI plus bevacizumab and FOLFIRI plus aflibercept had similar anti-tumor activities and toxicity profiles when used as second-line therapy in mCRC patients. Based on these data, both aflibercept and bevacizumab are suitable anti-angiogenic agents when used in combination with FOLFIRI for mCRC.

Fruquintinib combination with sintilimab in refractory metastatic colorectal cancer patients in China.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4028-4028 ◽  
Author(s):  
Miaomiao Gou ◽  
Huan Yan ◽  
Liu Tie E ◽  
Zhikuan Wang ◽  
Haiyan Si ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Human Monoclonal Antibody ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Once Daily ◽  
Anti Cancer ◽  
Vegfr Inhibitor ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

4028 Background: Fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, is a new anti-cancer targeting drug independently developed in China for refractory metastatic colorectal cancer (mCRC). Because Regorafenib combined with nivolumab has a promising future in patients with refractory mCRC, we aim to evaluate the efficiency of combination of Fruquintinib with Sintilimab (a highly selective, fully human monoclonal antibody PD-1 mAb) in these patients. Methods: Fifty-two patients with refractory mCRC were given fruquintinib (3mg orally, once daily for 3 weeks, followed by 1 weeks off in 4 weeks cycles) and sintilimab (200mg intravenously, once every 3 weeks). Before treatment, peripheral blood samples were collected and next-generation sequencing was performed to detect the gene profile of patients. Results: The ORR was 15.38% (8/52), DCR was 57.6% (30/52), and mPFS was 108 days. The patients was divided into two groups according to their PFS: PFS ≥ 90 days and PFS <90 days. PFS was significantly worse in patients with the following mutations: AMER1 ( p=0.0073), DNMT3A ( p=0.0075), ETV5 ( p=0.012), EWSR1 ( p=0.016), FANCA ( p=0.019), IKBKE ( p=0.0073), NOTCH1 ( p=0.015), STAG2 ( p=0.012) and TCF7L2 ( p=0.0073). It was also significantly worse in the patients had the abnormalities of complexity and coagulation cascades ( p = 0.026) and pancreatic cancer pathway ( p = 0.0098). Conclusions: Fruquintinib combined with Sintilimab seemed not resulted in a significant increase in ORR, DCR and OS in refractory mCRC. Certain mutational genes and abnormal pathway caused by some frameshift mutations may affect the efficacy. It is suggested that targeting these mutational genes and signaling pathway may be helpful to improve the efficacy of Fruquintinib combination with Sintilimab.

Sign in / Sign up

Export Citation Format

Share Document